|

|

close search icon

ABOUT
Company Profile Management Team Message from the CEO Corporate Culture Company History Honors and Awards

Over 18 years of experience in R&D Learn more
CLIENT CENTER
Intellectual Property Protection Downloads Partnerships Newsletters

Global

U.S.

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369
News
Medicilon Events Featured Stories Market Events Videos

2022-09-29 Medicilon Events

Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration

On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.

Learn more

2022-09-14 Medicilon Events

Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"

On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.

Learn more
INVESTORS
Stock Information Investment Contact

Medicilon

688202

RMB

As of

Beijing time

The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com
CAREERS
Talent Development Employee Activities Campus Recruitment Social Recruitment

Campus Recruitment

Campus Recruitment

Social Recruitment

Social Recruitment

© 2022 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 |Website Map

Close

ABOUT
Company Profile Management Team Honors and Awards Corporate Culture

SERVICES
Drug Discovery Pharmaceutical Research Preclinical Research

PLATFORM
One-stop Integrated Services Key Technical Services for Drug R&D Innovative Drug R&D Services Drug Efficacy Evaluation for Common Diseases Advanced Preparation R&D

CLIENT CENTER
Intellectual Property Protection Downloads Partnerships Newsletters

NEWS
Medicilon Events Featured Stories Market Events Videos

INVESTORS
Stock Information Investment Contact

CAREERS
Talent Development Employee Activities Campus Recruitment Social Recruitment

© 2022 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 |Website Map

Close

Contact Us

Business Inquiry

Global：

Email:marketing@medicilon.com

+1(626)986-9880(U.S. - West Coast)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

Message

Back To Top

Online Message×

Medicilon's News and Events

News and Events

Medicilon Events Featured Stories Market Events Videos

News and Events

Hot information：

Top 10 Global Clinical Research Organizations in 2021| Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Join Medicilon at Precision in Drug Discovery & Preclinical Summit|

Medicilon Events

More

2022-09-29 ·Medicilon Events

Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration

On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.

More

2022-09-14 ·Medicilon Events

Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"

On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.

More

2022-09-01 ·Medicilon Events

Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022

Shanghai Medicilon Inc. was invited to attend the GOI press conference. The Medicilian Academician Innovative Drug Maturation Center was selected as the 2022 Pudong Large Enterprise Open Innovation Center.

More

2022-09-29 ·Medicilon Events

Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform

Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.

2022-09-29 ·Medicilon Events

Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration

On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.

2022-09-26 ·Medicilon Events

The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held

On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park. This is another grand event following the opening of Medicilon (Hangzhou) on September 7.

2022-09-14 ·Medicilon Events

Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!

On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.

2022-09-14 ·Medicilon Events

Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"

On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.

2022-09-01 ·Medicilon Events

Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022

Shanghai Medicilon Inc. was invited to attend the GOI press conference. The Medicilian Academician Innovative Drug Maturation Center was selected as the 2022 Pudong Large Enterprise Open Innovation Center.

2022-08-29 ·Medicilon Events

Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use

On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors. CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.

2022-08-15 ·Medicilon Events

Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"

Recently, the SMDC released the list of the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022". With its strong scientific and technological innovation strength, Shanghai Medicilon Inc. stands out from many outstanding enterprises and ranks among the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022".

2022-08-15 ·Medicilon Events

Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"

On August 4, 2022, the 6th China Bio-Pharma Partnering Forum 2022 and the 2022 China Biomedical Industry Value List Award Ceremony was held, Shanghai Medicilon Inc. was on the list of the "Top 20 Most Influential CXO Enterprise."

Featured Stories

More

Top 10 Global CDMO in 2022

Top 10 Global CDMO in 2022

The ADC drug industry is thriving!

The ADC drug industry is thriving!

ALK inhibitors: iterative upgrade, targeted therapies strike with precision

ALK inhibitors: iterative upgrade, targeted therapies strike with precision

More

Market Events

More

Join Medicilon at the CBA Annual Conference 2022

Join Medicilon at the 2022 NESACS Annual Advances in Chemical Sciences Symposium meeting

Join Medcilon at the 2022 SAPA Annual Conference

Join Medicilon at the 20th San Diego BioPharma Conference

More

Video

More

Medicilon's Drug Discovery services: Chemical and Biological Services

Medicilon's Pharmaceutical Research services: Process chemistry and Formulation services

Medicilon Preclinical Research-Pharmacology, PK, and Safety Evaluation Services

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

© 2022 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy

bioanalytical testing IND Filing PROTAC API ADME Drug Discovery Animal Models Oral Solid Dosage PDX model Pharmacokinetics More